Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint

Efficacy of Injectable Platelet Rich Fibrin Versus Platelet Rich Plasma Injection in Degenerative Temporomandibular Joint

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07078006

Enrollment

Registered

2025-07-22

Start date

2023-02-22

Completion date

2024-07-23

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Temporomandibular Joint, Platelet Rich Fibrin, Platelet Rich Plasma Injection

Brief summary

The study aimed to compare the efficacy of injectable platelet rich fibrin (I-PRF) versus platelet rich plasma (PRP) injection in degenerative temporomandibular joint (TMJ).

Detailed description

Degenerative joint disease (DJD), a frequently observed as osteoarthritic condition in clinical practice, manifests as a persistent and continuous transformation in joint configuration due to the deterioration and attrition of articular cartilage, accompanied by modifications in the subchondral bone and other soft tissue. Treatment includes physical therapy, pulsed electrical stimulation, pharmacological, topical ointments, supplements, steroid injections, hyaluronic acid (HA) injections, and acupuncture. Further studies have been carried out to better investigate the effectiveness of different techniques to perform arthrocentesis by using growth factors, autologous solutions, or alternative materials; the materials most used are platelet-rich plasma (PRP) and HA in arthrocentesis or by injection.

Interventions

OTHERPlatelet Rich Fibrin

Patients underwent arthrocentesis followed by a platelet-rich fibrin (PRF) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

OTHERPlatelet Rich Plasma

Patients underwent arthrocentesis followed by a platelet-rich plasma (PRP) injection using a conventional temporomandibular joint (TMJ) injection technique, aided by facial anatomical landmarks.

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>18 years old. * Both sexes. * Patients with unilateral or bilateral temporomandibular joint (TMJ) osteoarthritis according to magnetic resonance imaging (MRI) evaluation.

Exclusion criteria

* Patients under any type of antiplatelet or anticoagulant medications. * Cardiovascular, renal, or hepatic disease. * Diabetes. * Anemia. * Vascular insufficiency. * Peripheral neuropathy. * Previous surgery for TMJ and rheumatoid arthritis.

Design outcomes

Primary

Measure	Time frame	Description
Pain improvement	6 months post-procedure	Each patient will be instructed about postoperative pain assessment with the Visual Analogue Scale (VAS). VAS (0 represents no pain while 10 represents the worst pain imaginable). VAS was recorded preoperatively, immediately after the procedures, 1 month, 3 months, and 6 months postoperatively.

Secondary

Measure	Time frame	Description
Assessment of tissue repair	6 months post-procedure	Tissue repair in the form of initiating fibrin coating around the osteoarthritic joint by using Magnetic Resonance Imaging (MRI) was recorded.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026